BioSpace News Archive

Aegis Sciences Corporation has expanded its molecular testing capabilities to rapidly identify pathogens in the respiratory and urogenital health spaces.

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the third quarter 2021 before the market opens on Wednesday, October 27, 2021, and will hold a conference call on the same day at 8:30 a.m. EDT.

Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII) will host a live webcast of its fiscal 2022 first-quarter conference call on Tuesday, November 9, 2021, at 8:00 a.m. CT (9:00 a.m. ET).

Omnicell, Inc. will release its financial results for the third quarter of 2021 before the open of the market on Tuesday, November 2, 2021.

Exscientia (Nasdaq: EXAI), the Medical University of Vienna and the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, today announced publication in Cancer Discovery, a journal of the American Association of Cancer Research, of final results from the EXALT-1 trial.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its third quarter 2021 financial and operating results on Thursday, November 4, 2021 , before the U.S. financial markets open.

Hanger, Inc. announced it will report its financial results for the third quarter and nine months ended September 30, 2021 after the stock market closes on Monday, November 8, 2021.

Aura Biosciences today announced the presentation of interim Phase 2 data with 7 months average follow up evaluating the safety of suprachoroidal (SC)

Sores that develop on the lining of stomach, esophagus, and intestines are called peptic ulcers. Symptoms of peptic ulcers include vomiting, burning stomach pain, bloating, and food intolerance.

Protalix BioTherapeutics, Inc. and Chiesi Global Rare Diseases provided a regulatory update regarding pegunigalsidase alfa for the proposed treatment of Fabry disease which included an announcement of the receipt of the official Type A meeting minutes from the U.S. FDA regarding the Complete Response Letter received for the PRX–102 Biologics License Application confirming a potential pathway for resubmission of a BLA for PRX–102.